Avalo Therapeutics Reports Widened 2025 Net Loss, Increased Cash Burn, and Significant Dilution Potential Amidst Insider Selling Plans
AVTX has more than doubled off its 52-week low of $3.39.
Summary
Avalo Therapeutics' 2025 annual report shows a widened net loss and increased cash burn, with significant potential dilution from its capital programs and notable insider selling plans, despite an extended cash runway into 2028.
Key Events · Earnings and Guidance · AVTX
-
Widened Net Loss and Increased Cash Burn
The company reported a net loss of $78.3 million for 2025, a significant increase from $35.1 million in 2024. Net cash used in operating activities also increased to $51.5 million in 2025 from $49.0 million in 2024.
-
Extended Cash Runway into 2028
Despite increased losses, Avalo Therapeutics projects its existing cash, cash equivalents, and short-term investments of $98.3 million (as of Dec 31, 2025) are sufficient to fund operations into 2028.
-
Significant Potential Dilution from Convertible Securities and ATM Program
As of December 31, 2025, 18,792 shares of Series C Preferred Stock were outstanding, convertible into approximately 18.8 million common shares. Additionally, the company sold 1.7 million common shares for $14.8 million under its $75.0 million At-The-Market (ATM) program in 2025, with approximately $60.2 million remaining available for future sales. If all convertible preferred stock and remaining ATM shares were issued, it would represent over 100% dilution to current outstanding common shares.
-
Multiple Insiders Adopt 10b5-1 Selling Plans
Five executive officers and directors adopted Rule 10b5-1 trading plans in November 2025 to sell an aggregate of 472,718 shares of common stock, valued at approximately $6.33 million based on the current stock price. This follows a Form 144 filing on March 16, 2026, for an officer to sell shares worth approximately $466,558.
Analysis · AVTX · Life Sciences
Avalo Therapeutics' 2025 annual report reveals a substantial deterioration in financial performance, marked by a significantly increased net loss and higher cash burn. While the company projects a cash runway into 2028, this is set against a backdrop of considerable dilution from its ATM program and convertible preferred stock. The adoption of 10b5-1 selling plans by multiple executives and directors signals a lack of insider conviction, further compounded by the recent expiration of the composition-of-matter patent for its lead candidate, AVTX-009. Investors should closely monitor the upcoming Phase 2 LOTUS trial data in Q2 2026, as it is a critical catalyst for the company's future, but remain cautious given the current financial strain and potential for further dilution.
At the time of this filing, AVTX was trading at $13.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $248.4M. The 52-week trading range was $3.39 to $20.72. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.